Pioglitazone for Heroin and for Nicotine Dependence



Status:Completed
Conditions:Smoking Cessation, Psychiatric, Tobacco Consumers
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:21 - 55
Updated:3/16/2015
Start Date:March 2011
End Date:February 2016
Contact:Gabriela Madera, BS
Email:maderag@pi.cpmc.columbia.edu
Phone:212-543-5319

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Effects of Pioglitazone, a PPARγ Agonist, on the Abuse Liability of Heroin and of Nicotine

The goal of the proposed research is to improve the effectiveness of treatments for opioid
and for nicotine dependence by testing a novel pharmacological strategy. Specifically,
pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be
used as an adjunct to agonist-based treatment.

Although treatments for opioid and for nicotine dependence exist, these medications are not
universally effective as many patients are unable to stop using or relapse rapidly,
suggesting that treatment with a single agent alone is insufficient to facilitate cessation
of use in many patients. Targeting additional pathways that may contribute to the
maintenance of drug-taking behaviors or relapse may be a more effective strategy to treat
individuals resistant to first-line approaches.

Inclusion Criteria:

- 21-55 years of age

- Physically healthy

- Able to perform study procedures

Exclusion Criteria:

- Pregnancy

- Physical dependence on any other drugs besides caffeine, heroin and nicotine
We found this trial at
1
site
New York State Psychiatric Institute
1051 Riverside Dr
New York, New York 10032
646-774-5000
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
?
mi
from
New York, NY
Click here to add this to my saved trials